

Guidance for the Management of Patients with Vascular
Factors and COVID-19: Position Paper from VAS-Europe
Angiology/Vascular Medicine

Thrombosis and Haemostasis

120, 1597-1628

DOI: [10.1055/s-0040-1715798](https://doi.org/10.1055/s-0040-1715798)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | COVID-19 and the newly rediscovered multidisciplinary. <i>Immunotherapy</i> , 2020, 12, 1101-1103. | 1.0 | 4 |
| 2 | Angiotensin II, III, and IV may be important in the progression of COVID-19. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020, 21, 147032032097201. | 1.0 | 6 |
| 3 | Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. primary and community healthcare. <i>Toxicology Reports</i> , 2021, 8, 1-9. | 1.6 | 80 |
| 4 | Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 223, 933-944. | 1.9 | 113 |
| 5 | Anticoagulant treatment in COVID-19: a narrative review. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 642-648. | 1.0 | 68 |
| 6 | Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1054-1065. | 1.8 | 87 |
| 7 | Waves of SARS-CoV-2 Infection and Blood Coagulation—A Link and Beyond. <i>Thrombosis and Haemostasis</i> , 2021, 121, 004-006. | 1.8 | 4 |
| 8 | Pulmonary artery thrombosis: clinical aspects and mechanism. <i>Kardiologiya I Serdechno-Sosudistaya Khirurgiya</i> , 2021, 14, 213. | 0.1 | 0 |
| 9 | Thrombosis and Haemostasis 2020 Editors' Choice Papers. <i>Thrombosis and Haemostasis</i> , 2021, 121, 109-114. | 1.8 | 4 |
| 10 | Looking Back on 2020, Looking Forward to 2021. <i>Thrombosis and Haemostasis</i> , 2021, 121, 001-003. | 1.8 | 4 |
| 11 | A Matter of Caution: Coagulation Parameters in COVID-19 Do Not Differ from Patients with Ruled-Out SARS-CoV-2 Infection in the Emergency Department. <i>TH Open</i> , 2021, 05, e43-e55. | 0.7 | 15 |
| 12 | Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 897-901. | 1.0 | 39 |
| 14 | Coronavirus disease 2019: a comprehensive review and meta-analysis on cardiovascular biomarkers. <i>Current Opinion in Cardiology</i> , 2021, 36, 367-373. | 0.8 | 10 |
| 15 | Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 944-954. | 1.8 | 59 |
| 16 | Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California. <i>JAMA Internal Medicine</i> , 2021, 181, 997. | 2.6 | 34 |
| 17 | Anticoagulant Treatment of COVID-19 as Early as Possible—Sulodexide and Perspectives. <i>Thrombosis and Haemostasis</i> , 2021, 121, 849-853. | 1.8 | 5 |
| 19 | Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141. | 1.8 | 55 |
| 20 | D-Dimer Level and Neutrophils Count as Predictive and Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19 Patients. <i>Viruses</i> , 2021, 13, 758. | 1.5 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 21 | Venous thromboembolism in COVID-19: A systematic review and meta-analysis. <i>Vascular Medicine</i> , 2021, 26, 415-425. | 0.8 | 136 |
| 22 | Symptomatic Common Carotid Free-Floating Thrombus in a COVID-19 Patient, Case Report and Literature Review. <i>Annals of Vascular Surgery</i> , 2021, 73, 122.e1-122.e7. | 0.4 | 21 |
| 23 | Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , 2021, 235, 12-23. | 1.2 | 36 |
| 24 | Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: A propensity score-matched cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4839-4847. | 1.1 | 21 |
| 25 | Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. <i>Blood</i> , 2021, 137, 2838-2847. | 0.6 | 133 |
| 27 | Predictive value of D-dimer/albumin ratio and fibrinogen/albumin ratio for in-hospital mortality in patients with COVID-19. <i>International Journal of Clinical Practice</i> , 2021, 75, e14263. | 0.8 | 19 |
| 28 | Obesity and COVID-19: the ominous duet affecting the renin-angiotensin system. <i>Minerva Endocrinology</i> , 2021, 46, 193-201. | 0.6 | 13 |
| 29 | The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021, 121, 992-1007. | 1.8 | 21 |
| 30 | Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. <i>CJC Open</i> , 2021, 3, 1257-1272. | 0.7 | 18 |
| 31 | Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2490. | 1.0 | 56 |
| 32 | COVID-19 and ischemic stroke. <i>European Journal of Neurology</i> , 2021, 28, 3826-3836. | 1.7 | 55 |
| 33 | Albumin Infusion in Critically Ill COVID-19 Patients: Hemodilution and Anticoagulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7126. | 1.8 | 14 |
| 34 | Outpatient Management of COVID-19 Disease: A Holistic Patient-Centered Proposal Based on the Greek Experience. <i>Journal of Personalized Medicine</i> , 2021, 11, 709. | 1.1 | 1 |
| 35 | Risk factors for mortality of adult patients with COVID-19 hospitalised in an emerging country: a cohort study. <i>BMJ Open</i> , 2021, 11, e050321. | 0.8 | 17 |
| 36 | Thromboprophylaxis strategies to improve the prognosis of COVID-19. <i>Vascular Pharmacology</i> , 2021, 139, 106883. | 1.0 | 7 |
| 37 | Cardiovascular Risk Assessment in COVID-19. <i>Hamostaseologie</i> , 2021, 41, 350-355. | 0.9 | 0 |
| 38 | Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review. <i>Digestive and Liver Disease</i> , 2021, 53, 937-949. | 0.4 | 16 |
| 39 | Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. <i>Biomedicines</i> , 2021, 9, 966. | 1.4 | 111 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 40 | Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. <i>Cardiovascular Diabetology</i> , 2021, 20, 172. | 2.7 | 271 |
| 41 | Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports. <i>Current Vascular Pharmacology</i> , 2022, 20, 96-110. | 0.8 | 22 |
| 42 | Persistent Endothelial Dysfunction in Post-Acute COVID-19 Syndrome: A Case-Control Study. <i>Biomedicines</i> , 2021, 9, 957. | 1.4 | 61 |
| 43 | COVID-19 Immunobiology: Lessons Learned, New Questions Arise. <i>Frontiers in Immunology</i> , 2021, 12, 719023. | 2.2 | 28 |
| 44 | Thromboprophylaxis in COVID-19: Early initiation might be as important as optimal dosing. <i>Thrombosis Research</i> , 2021, 204, 134-135. | 0.8 | 8 |
| 45 | Post-Discharge Prophylactic Anticoagulation in COVID-19 Patients: A Clinical Dilemma. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2021, 21, 206-209. | 0.2 | 2 |
| 46 | COVID-19 and aortic disease: a practical systematic review of the literature on management and outcomes. <i>Journal of Cardiovascular Surgery</i> , 2022, 62, . | 0.3 | 1 |
| 47 | Peripheral artery disease, the "lost syndrome"™ during lockdown for COVID-19: A report of three cases. <i>Medicine International</i> , 2021, 1, . | 0.2 | 2 |
| 48 | Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. <i>Cardiovascular Diabetology</i> , 2021, 20, 176. | 2.7 | 10 |
| 49 | Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban Therapy: Rationale and Design of the MICHELLE Trial. <i>American Heart Journal</i> , 2021, 242, 115-122. | 1.2 | 18 |
| 50 | Anticoagulation for COVID-19 Patients: A Bird's-Eye View. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110392. | 0.7 | 10 |
| 51 | Increased Risk of e-Thrombosis in e-Life Era. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110282. | 0.7 | 0 |
| 53 | Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 076-085. | 1.8 | 52 |
| 54 | Persistence of Antibody Responses to the SARS-CoV-2 in Dialysis Patients and Renal Transplant Recipients Recovered from COVID-19. <i>Pathogens</i> , 2021, 10, 1289. | 1.2 | 4 |
| 55 | Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts. <i>Thrombosis Research</i> , 2021, 208, 4-10. | 0.8 | 14 |
| 56 | Clinical Features and Management of COVID-19 Associated Hypercoagulability. <i>Cardiac Electrophysiology Clinics</i> , 2021, 14, 41-52. | 0.7 | 2 |
| 57 | Cardiovascular medicine: a year in review. <i>Minerva Cardiology and Angiology</i> , 2021, . . | 0.4 | 4 |
| 58 | Update on the management of vascular patients with COVID-19. <i>Journal of Theoretical and Applied Vascular Research</i> , 2020, 5, . | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 60 | Virchow's Triad and the Role of Thrombosis in COVID-Related Stroke. <i>Frontiers in Physiology</i> , 2021, 12, 769254. | 1.3 | 15 |
| 61 | Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. <i>Thrombosis Journal</i> , 2021, 19, 91. | 0.9 | 12 |
| 62 | Molecular mechanisms of hemostasis activation in COVID-19 at the hospital stage. <i>Laboratornaya Sluzhba</i> , 2021, 10, 25. | 0.0 | 1 |
| 63 | Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 784505. | 1.8 | 5 |
| 64 | Thrombosis and Haemostasis 2021 Editors' Choice Papers. <i>Thrombosis and Haemostasis</i> , 2022, 122, 163-170. | 1.8 | 2 |
| 65 | Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. <i>Lancet</i> , The, 2022, 399, 50-59. | 6.3 | 172 |
| 66 | Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery: The Prospective Observational ROADMAP-Post COVID-19 Study. <i>Hemato</i> , 2022, 3, 111-121. | 0.2 | 4 |
| 67 | Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. <i>Respiration</i> , 2022, 101, 307-320. | 1.2 | 5 |
| 68 | Thromboprophylaxis in Patients With COVID-19. <i>Chest</i> , 2022, 162, 213-225. | 0.4 | 58 |
| 69 | Assessment of Thromboembolism Risk in COVID-19 Patients with Cardiovascular Disease Risk Factors: Analysis from the Japanese Nationwide Registry. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 70 | Revascularization prevents amputation among patients with diabetic foot during the COVID-19 era. <i>Vascular</i> , 2023, 31, 729-736. | 0.4 | 3 |
| 71 | The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. <i>Hemato</i> , 2022, 3, 204-218. | 0.2 | 0 |
| 72 | Analytical mapping of information and communication technology in emerging infectious diseases using CiteSpace. <i>Telematics and Informatics</i> , 2022, 69, 101796. | 3.5 | 27 |
| 73 | Persistent Lung Injury and Prothrombotic State in Long COVID. <i>Frontiers in Immunology</i> , 2022, 13, 862522. | 2.2 | 15 |
| 74 | Variáveis associadas ao desfecho clínico de pacientes hospitalizados por COVID-19. , 2021, 100, 431-441. | 0.0 | 1 |
| 75 | Acute lower limb ischemia in an ICU admitted patient diagnosed with the COVID-19: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05146. | 0.2 | 2 |
| 76 | Early Occurrence of Adverse Events in Hospitalized Patients With COVID-19 and Beneficial Effect of Anticoagulation. <i>In Vivo</i> , 2022, 36, 381-383. | 0.6 | 3 |
| 77 | COVID-19 related thrombosis: A mini-review. <i>Phlebology</i> , 2022, 37, 326-337. | 0.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 78 | A review of the presentation and outcome of left ventricular thrombus in coronavirus disease 2019 infection.. Journal of Clinical and Translational Research, 2021, 7, 797-808. | 0.3 | 6 |
| 79 | SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review. Biomedicines, 2022, 10, 962. | 1.4 | 6 |
| 80 | Stroke Recovery During the COVID-19 Pandemic: A Position Paper on Recommendations for Rehabilitation. Archives of Physical Medicine and Rehabilitation, 2022, 103, 1874-1882. | 0.5 | 12 |
| 81 | Critical Clinical Evaluation of Covid-19 Patients with Tuberculosis in the Indian Sub-Continent. Current Drug Safety, 2022, 17, . | 0.3 | 1 |
| 82 | Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry. International Journal of Clinical Practice, 2022, 2022, 1-9. | 0.8 | 1 |
| 83 | To escalate thromboprophylactic heparin intensity in COVID-19 or not? That is still the question. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12738. | 1.0 | 2 |
| 84 | Application of the ICF and OTPF-4 to Conceptualize the Dual Diagnosis of COVID-19 and Stroke: Implications for Occupational Therapy Practice in Acute and Inpatient Rehabilitation. Occupational Therapy in Health Care, 0, , 1-19. | 0.2 | 1 |
| 85 | Usefulness of C2HEST Score in Predicting Clinical Outcomes of COVID-19 in Heart Failure and Non-Heart-Failure Cohorts. Journal of Clinical Medicine, 2022, 11, 3495. | 1.0 | 2 |
| 86 | Evaluation of the Clinical Effects of an Antiviral, Immunostimulant and Antioxidant Phytotherapy in Patients Suffering from COVID-19 Infection: An Observational Pilot Study. International Journal of Translational Medicine, 2022, 2, 242-251. | 0.1 | 0 |
| 87 | Assessment of thromboembolism risk in COVID-19 patients with cardiovascular disease risk factors: Analysis of a Japanese Nationwide Registry. Thrombosis Research, 2022, 216, 90-96. | 0.8 | 1 |
| 88 | Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendationsâ€“State-of-the-Art. Anticancer Research, 2022, 42, 3261-3274. | 0.5 | 5 |
| 89 | Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients. Expert Review of Hematology, 2022, 15, 597-605. | 1.0 | 6 |
| 90 | Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211204. | 0.7 | 3 |
| 91 | The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology. Critical Reviews in Clinical Laboratory Sciences, 2023, 60, 25-40. | 2.7 | 4 |
| 92 | The role of platelets, neutrophils and endothelium in COVID-19 infection. Expert Review of Hematology, 2022, 15, 727-745. | 1.0 | 7 |
| 93 | The Usefulness of the C2HEST Risk Score in Predicting Clinical Outcomes among Hospitalized Subjects with COVID-19 and Coronary Artery Disease. Viruses, 2022, 14, 1771. | 1.5 | 0 |
| 94 | Hyperkalemia: do you forget something?. Internal and Emergency Medicine, 0, , . | 1.0 | 0 |
| 95 | The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 96 | SARS-CoV-2 Infection-Associated Aortic Thrombosis Treated with Oral Factor Xa Inhibition. Case Reports in Hematology, 2022, 2022, 1-3. | 0.3 | 0 |
| 97 | Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes. PLoS ONE, 2022, 17, e0270195. | 1.1 | 3 |
| 98 | Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records. TH Open, 2022, 06, e408-e420. | 0.7 | 5 |
| 100 | Ileocolic Thrombophlebitis and Lymphadenitis Mimicking Acute Appendicitis as a Late Manifestation in a COVID-19 Patient: A Case Report. Cureus, 2022, , . | 0.2 | 0 |
| 101 | Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared to the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness. Seminars in Thrombosis and Hemostasis, 2022, 48, 858-868. | 1.5 | 26 |
| 102 | Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovascular Diabetology, 2022, 21, . | 2.7 | 62 |
| 103 | Venous thromboembolism in COVID-19. Journal of King Abdulaziz University, Islamic Economics, 2022, 43, 979-990. | 0.5 | 1 |
| 104 | Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals. Thrombosis and Haemostasis, 2023, 123, 186-191. | 1.8 | 4 |
| 105 | Coagulation Profile of COVID-19 Patients. Life, 2022, 12, 1658. | 1.1 | 3 |
| 106 | Narrative Review of New Insight into the Influence of the COVID-19 Pandemic on Cardiovascular Care. Medicina (Lithuania), 2022, 58, 1554. | 0.8 | 1 |
| 107 | COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. Seminars in Thrombosis and Hemostasis, 2023, 49, 816-832. | 1.5 | 12 |
| 108 | Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. Journal of Clinical Medicine, 2022, 11, 5997. | 1.0 | 13 |
| 109 | Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients. Acta Haematologica, 2023, 146, 151-160. | 0.7 | 0 |
| 110 | Hypercoagulability in critically ill patients with COVID 19, an observational prospective study. PLoS ONE, 2022, 17, e0277544. | 1.1 | 5 |
| 112 | The Effect of COVID-19 Vaccines on Stroke Outcomes: A Single-Center Study. World Neurosurgery, 2023, 170, e834-e839. | 0.7 | 2 |
| 113 | Small molecules in the treatment of COVID-19. Signal Transduction and Targeted Therapy, 2022, 7, . | 7.1 | 42 |
| 114 | Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions. MedComm, 2022, 3, . | 3.1 | 6 |
| 115 | A Happy New Year 2023 from Thrombosis and Haemostasis. Thrombosis and Haemostasis, 2023, 123, 001-005. | 1.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 116 | Cardiovascular Disease Management in the Context of Global Crisis. International Journal of Environmental Research and Public Health, 2023, 20, 689. | 1.2 | 7 |
| 118 | Disfunção endotelial e Aterosclerose. Brazilian Journal of Health Review, 2022, 5, 25410-25410. | 0.0 | 0 |
| 119 | Coronavirus disease 2019 infection and cerebrovascular diseases: an update on the pathophysiology and management. Current Opinion in Neurology, 2023, 36, 155-164. | 1.8 | 1 |
| 120 | The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. Frontiers in Cardiovascular Medicine, 0, 10, . | 1.1 | 17 |
| 121 | Causal associations and shared genetics between hypertension and COVID-19. Journal of Medical Virology, 2023, 95, . | 2.5 | 11 |
| 127 | Infektionskrankheiten und Impfungen. , 2023, , 205-216. | | 0 |